{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:06:24Z","timestamp":1785744384214,"version":"3.56.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T00:00:00Z","timestamp":1486080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0171066","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T13:47:17Z","timestamp":1486129637000},"page":"e0171066","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study"],"prefix":"10.1371","volume":"12","author":[{"given":"Hitoshi","family":"Kawazoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Takechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Yakushijin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Moriguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,2,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"GV Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2008.20.9114","article-title":"Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer","volume":"27","author":"BH Gr\u00f8nberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","article-title":"Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial","volume":"13","author":"L Paz-Ares","year":"2012","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1200\/JCO.2012.47.9626","article-title":"PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer","volume":"31","author":"JD Patel","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2012.42.3749","article-title":"Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089)","volume":"31","author":"F Barlesi","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1200\/JCO.2015.64.3635","article-title":"Antiemetics: American Society of Clinical Oncology Focused Guideline Update","volume":"34","author":"PJ Hesketh","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/030089160709300205","article-title":"Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma","volume":"93","author":"M Tiseo","year":"2007","journal-title":"Tumori"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2004.00.9720","article-title":"Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function","volume":"24","author":"AC Mita","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00280-005-0036-1","article-title":"Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients","volume":"57","author":"JE Latz","year":"2006","journal-title":"Cancer Chemoth Pharm"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/1078-0432.CCR-05-1834","article-title":"Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer","volume":"12","author":"CJ Sweeney","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"EJ Lewis","year":"2001","journal-title":"New Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"HH Parving","year":"2001","journal-title":"New Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2337\/dc06-2493","article-title":"Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART)","volume":"30","author":"T Uzu","year":"2007","journal-title":"Diabetes Care"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc06-1998","article-title":"Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes","volume":"30","author":"H Makino","year":"2007","journal-title":"Diabetes Care"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"BM Brenner","year":"2001","journal-title":"New Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"AH Calvert","year":"1989","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/j.1349-7006.2010.01729.x","article-title":"Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer","volume":"101","author":"T Shimokata","year":"2010","journal-title":"Cancer Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2133\/dmpk.19.369","article-title":"Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3","volume":"19","author":"Y Uwai","year":"2004","journal-title":"Drug Metab Pharmacok"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0140-6736(86)91706-X","article-title":"Acute renal failure due to concomitant action of methotrexate and indomethacin","volume":"1","author":"AG Maiche","year":"1986","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0140-6736(86)90786-5","article-title":"Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen","volume":"327","author":"A Thyss","year":"1986","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2133\/dmpk.DMPK-13-RG-042","article-title":"Characteristics of pemetrexed transport by renal basolateral organic anion transporter hOAT3","volume":"29","author":"T Kurata","year":"2014","journal-title":"Drug Metab Pharmacok"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1124\/dmd.114.059618","article-title":"Prediction of renal transporter mediated drug\u2013drug interactions for pemetrexed using physiologically based pharmacokinetic modeling","volume":"43","author":"MM Posada","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1248\/bpb.b15-00162","article-title":"Risk factors for predicting severe neutropenia induced by pemetrexed plus carboplatin therapy in patients with advanced non-small cell lung cancer","volume":"38","author":"H Ikesue","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jjco\/hyn024","article-title":"Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I\/II study in Japanese patients","volume":"38","author":"K Nakagawa","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1248\/yakushi.13-00180","article-title":"Analysis of risk factors for severe adverse events of chemotherapy with pemetrexed and comparison of adverse event occurrence according to renal function","volume":"133","author":"Y Sakata","year":"2013","journal-title":"Yakugaku Zasshi"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1634\/theoncologist.2011-0431","article-title":"Accumulating evidence for a drug\u2013drug interaction between methotrexate and proton pump inhibitors","volume":"17","author":"S Bezabeh","year":"2012","journal-title":"Oncologist"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2125.2008.03303.x","article-title":"Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy","volume":"67","author":"K Suzuki","year":"2009","journal-title":"Brit J Clin Pharmaco"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bcp.12384","article-title":"Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors","volume":"78","author":"DJ Reeves","year":"2014","journal-title":"Brit J Clin Pharmaco"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0171066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T03:15:35Z","timestamp":1568776535000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0171066"}},"subtitle":[],"editor":[{"given":"Aamir","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,2,3]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0171066","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,3]]}}}